New drug SIBP-A10 tested in patients with advanced cancer
NCT ID NCT07205198
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new drug called SIBP-A10 in 160 adults with advanced tumors that have not responded to other treatments. The main goal is to check the drug's safety and find the best dose for future studies. Participants will receive the drug and be monitored for side effects and how the drug moves through their body.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhongshan Hospital Affiliated to Dalian University
RECRUITINGDalian, Liaoning, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new targeted pill tame advanced cancers? a phase i trial seeks answers
- New drug combo aims to boost immune attack on Hard-to-Treat cancers
- New antibody aims to unleash immune system against advanced tumors
- Double antibody attack: early trial combines immune and Growth-Signal blockers against advanced cancers
- New pill takes on advanced cancers in first human test
- New hope for advanced cancer: LBL-024 trial now recruiting